Antonio Jimeno Selected Research

PX-866

12/2016	A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.
4/2015	A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
12/2014	A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.
8/2013	A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
8/2012	A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Antonio Jimeno Research Topics

Disease

116	Neoplasms (Cancer) 03/2022 - 06/2004
36	Squamous Cell Carcinoma of Head and Neck 03/2022 - 08/2004
21	Pancreatic Neoplasms (Pancreatic Cancer) 12/2012 - 04/2005
12	Colorectal Neoplasms (Colorectal Cancer) 12/2016 - 12/2005
10	Disease Progression 06/2016 - 12/2004
9	Head and Neck Neoplasms (Head and Neck Cancer) 01/2022 - 11/2010
8	Neoplasm Metastasis (Metastasis) 10/2020 - 06/2005
7	Ovarian Neoplasms (Ovarian Cancer) 01/2019 - 04/2007
5	Carcinoma (Carcinomatosis) 03/2022 - 10/2006
5	Adenocarcinoma 01/2020 - 04/2006
5	Fatigue 12/2017 - 12/2010
5	Squamous Cell Neoplasms (Squamous Cell Cancer) 12/2016 - 08/2013
5	Prostatic Neoplasms (Prostate Cancer) 06/2010 - 12/2004
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 01/2012
4	Exanthema (Rash) 11/2018 - 10/2007
3	Anemia 11/2018 - 09/2008
3	Fever (Fevers) 11/2018 - 06/2004
3	Neutropenia 01/2017 - 06/2004
3	Lung Neoplasms (Lung Cancer) 01/2017 - 04/2005
3	Nausea 01/2017 - 12/2012
3	Carcinogenesis 01/2015 - 01/2012
3	Systemic Lupus Erythematosus (Libman-Sacks Disease) 11/2012 - 03/2010
3	Diarrhea 08/2012 - 10/2007
2	Bites and Stings (Sting) 10/2021 - 01/2018
2	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2021 - 04/2005
2	Melanoma (Melanoma, Malignant) 01/2021 - 01/2005
2	Chills 11/2018 - 06/2015
2	Spasm (Spasms) 12/2017 - 05/2013
2	Vomiting 01/2017 - 12/2012
2	Headache (Headaches) 12/2016 - 06/2015
2	Febrile Neutropenia 01/2016 - 06/2004
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2015 - 06/2015

Drug/Important Bio-Agent (IBA)

24	ErbB Receptors (EGF Receptor)IBA 01/2022 - 04/2005
21	Biomarkers (Surrogate Marker)IBA 10/2021 - 02/2006
18	Pharmaceutical PreparationsIBA 10/2020 - 03/2005
17	Cetuximab (Erbitux)FDA Link 10/2021 - 04/2005
16	Proteins (Proteins, Gene)FDA Link 10/2021 - 04/2005
13	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2017 - 04/2005
12	Biological ProductsIBA 10/2020 - 12/2004
10	Phosphotransferases (Kinase)IBA 01/2017 - 07/2006
9	Messenger RNA (mRNA)IBA 10/2021 - 04/2005
9	Gemcitabine FDA Link 04/2012 - 09/2003
8	Monoclonal AntibodiesIBA 01/2019 - 04/2007
8	LigandsIBA 01/2019 - 06/2015
6	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 12/2016 - 04/2011
6	Tyrosine Kinase InhibitorsIBA 10/2015 - 12/2006
5	CateninsIBA 03/2018 - 10/2013
5	PX-866IBA 12/2016 - 08/2012
5	ON 01910IBA 03/2014 - 09/2007
5	Polo-Like Kinase 1IBA 03/2014 - 12/2008
5	Gefitinib (Iressa)FDA Link 09/2007 - 05/2005
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 08/2006
4	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 08/2004
4	Docetaxel (Taxotere)FDA Link 01/2020 - 01/2006
4	PlatinumIBA 01/2019 - 12/2015
4	Cisplatin (Platino)FDA LinkGeneric 12/2016 - 03/2011
4	TOR Serine-Threonine KinasesIBA 12/2016 - 06/2009
4	Capecitabine (Xeloda)FDA Link 01/2016 - 09/2008
4	Antineoplastic Agents (Antineoplastics)IBA 08/2013 - 07/2006
4	AtrasentanIBA 10/2006 - 12/2004
3	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2022 - 10/2013
3	Small Interfering RNA (siRNA)IBA 11/2019 - 04/2005
3	MEHD7945AIBA 12/2016 - 06/2015
3	tyrosine receptor (receptor, tyrosine)IBA 12/2016 - 04/2007
3	IPI-926IBA 02/2016 - 05/2013
3	Bevacizumab (Avastin)FDA Link 01/2016 - 04/2007
3	DNA (Deoxyribonucleic Acid)IBA 01/2015 - 09/2008
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2015 - 04/2007
3	cyclopamineIBA 12/2014 - 03/2007
3	Panitumumab (Vectibix)FDA Link 04/2010 - 03/2009
3	temsirolimus FDA Link 06/2009 - 02/2007
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2008 - 12/2006
2	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 12/2016
2	Transforming Growth Factor beta (TGF-beta)IBA 01/2021 - 01/2015
2	durvalumabIBA 10/2020 - 01/2019
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020 - 12/2010
2	CytokinesIBA 11/2019 - 11/2010
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 04/2007
2	OMP-54F28IBA 01/2019 - 02/2015
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2018 - 12/2009
2	nirogacestatIBA 03/2018 - 01/2015
2	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 03/2018 - 01/2015
2	EnzymesIBA 01/2018 - 12/2010
2	Ephrin-B2 (Ephrin B2)IBA 01/2018 - 01/2017
2	src-Family KinasesIBA 01/2017 - 06/2009
2	Transaminases (Aminotransferases)IBA 01/2017 - 09/2008
2	Aldehyde DehydrogenaseIBA 01/2017 - 09/2010
2	CreatinineIBA 01/2017 - 12/2012
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 12/2016 - 04/2015
2	Neuregulin-1 (Neuregulin 1)IBA 01/2016 - 06/2015
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2016 - 03/2008
2	Tumor Biomarkers (Tumor Markers)IBA 10/2015 - 01/2012
2	TropomyosinIBA 10/2015 - 12/2012

Therapy/Procedure

46	Therapeutics 03/2022 - 08/2004
17	Drug Therapy (Chemotherapy) 01/2019 - 06/2004
12	Radiotherapy 10/2020 - 11/2010
7	Immunotherapy 01/2021 - 05/2014
3	Chemoradiotherapy 01/2020 - 08/2004
2	Oral Administration 01/2022 - 01/2015
2	Aftercare (After-Treatment) 01/2017 - 02/2016